Back to Dsip research
dsip preclinical animal n preclinical 2026-04-24 PubMed

Phosphorylated DSIP restores spatial memory by improving sleep architecture in rats at high altitude

Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude.

Background

Exposure to high altitude often leads to sleep loss and hypobaric hypoxia, which can severely impair neuropsychological functions like memory, attention, and decision-making. The underlying biochemical mechanisms involve alterations in brain monoamine levels and signaling pathways crucial for memory consolidation, such as the CREB (cAMP response element-binding protein) pathway. Specifically, reduced phosphorylation of CREB (p-CREB) in the hippocampus is linked to memory deficits. Delta sleep-inducing peptide (DSIP), particularly its more stable phosphorylated form (p-DSIP), is known to modulate sleep. This study investigates if p-DSIP can counteract the negative neurological effects of high altitude by improving sleep architecture and restoring critical memory-related molecular pathways.

Study Design

Morris Water Maze (MWM) trained rats were exposed to simulated high altitude (chronic hypobaric hypoxia at 7620 m). The intervention group received daily intraperitoneal injections of p-DSIP (10 μg/Kg bw) during their circadian active period (18:30 h). Sleep architecture was monitored telemetrically. Brain tissue from the hippocampus, brain stem, and hypothalamus was analyzed post-exposure. Monoamine levels were measured via HPLC, and key proteins (CREB, p-CREB) were quantified using Western blotting. Regulatory enzyme expression (TH, MAO A, GAD, ChAT) was measured by flow cytometry. A separate group received the μ-opioid receptor antagonist naloxone (1 mg/kg bw) to investigate its role in blocking p-DSIP's effects.

Results

Daily p-DSIP administration during high-altitude exposure significantly enhanced both non-rapid eye movement (NREM) and rapid eye movement (REM) sleep. This improvement in sleep architecture was directly linked to better cognitive performance, as evidenced by improved performance in the MWM spatial memory task. On a molecular level, p-DSIP treatment lowered monoamine levels and decreased Tyrosine Hydroxylase (TH) expression in the brain stem. Conversely, it increased the expression of Monoamine Oxidase A (MAO A), Glutamic Acid Decarboxylase (GAD), and Choline Acetyltransferase (ChAT). Critically, p-DSIP treatment restored hippocampal levels of phosphorylated CREB (p-CREB), a key molecule for memory formation.

The administration of naloxone, a μ-opioid receptor antagonist, blocked the sleep-inducing effects of p-DSIP, which subsequently altered navigational memory and decreased both CREB and p-CREB levels in the hippocampus, confirming the pathway's dependence on p-DSIP's sleep-promoting action.

Key Findings

  • p-DSIP (10 μg/Kg bw) injected daily during chronic hypobaric hypoxia enhanced NREM and REM sleep in rats.
  • p-DSIP treatment improved Morris Water Maze performance, restoring spatial navigational memory.
  • p-DSIP increased the expression of brain stem enzymes MAO A, GAD, and ChAT while decreasing TH.
  • The peptide restored hippocampal p-CREB levels, which were suppressed by hypoxia.
  • Naloxone (1 mg/kg bw) reversed the memory-restoring effects of p-DSIP by suppressing p-CREB levels.

Why It Matters

This research provides a mechanism-backed rationale for using p-DSIP to mitigate cognitive decline caused by high-altitude environments. For individuals operating at altitude (mountaineers, aviators, military personnel), this suggests a potential prophylactic or therapeutic strategy to preserve memory and decision-making by targeting sleep quality. The finding that p-DSIP restores spatial memory by up-regulating CREB phosphorylation via sleep improvement offers a specific pathway for intervention. While this is an animal study, it establishes a strong preclinical basis for exploring p-DSIP in humans facing similar hypoxic stressors. The specific timing of administration (circadian active period) also provides a valuable data point for future protocol design, suggesting that timing may be critical for efficacy. Further studies would be needed to determine human-equivalent dosing and safety.

TitrateLab articles covering DSIP

Written by TitrateLab, separately from the study summarized above.


dsip μ-opioid-receptor dose mentioned dsip p-dsip sleep high altitude hypoxia neuroprotection
Source: pubmed:30107169 · Ingested Apr 24, 2026 · Digest: gemini-2.5-pro